Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

被引：0
|
作者：
Yang, J. [1 ]
Cheng, Y. [2 ]
Murakami, H. [3 ]
Yang, P-C. [1 ]
He, J. [4 ]
Nakagawa, K. [5 ]
Kang, J. H. [6 ]
Kim, J-H. [7 ]
Hozak, R. [8 ]
Nguyen, T. [9 ]
Wang, X. [10 ]
Enatsu, S. [11 ]
Puri, T. [12 ]
Orlando, M. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China
[3] Shizuoka Canc Ctr, Dept Oncol, Shizuoka, Japan
[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Oncol, Guangzhou, Guangdong, Peoples R China
[5] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[6] Catholic Univ Korea, Dept Med Oncol, Seoel, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea
[8] Eli Lilly & Co, Oncol Business Unit, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Oncol Tailoring Biomarker Stat, Indianapolis, IN 46285 USA
[10] Eli Lilly & Co, Med Dev Unit, Shanghai, Peoples R China
[11] Eli Lilly Japan KK, Med Dev Unit, Kobe, Hyogo, Japan
[12] Eli Lilly & Co, Med Affairs, Gurgaon, India
[13] Eli Lilly & Co, Emerging Markets Med Affairs, Buenos Aires, Argentina
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1240P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FIRST-LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR plus ) NON-SMALL CELL LUNG CANCER (NSCLC) IN AN ISRAELI COHORT
    Ben-Arieh, S.
    Urban, D.
    Maimon, N.
    Leibowitz-Amit, R.
    Keizman, D.
    Biran, H.
    Mishaeli, M.
    Onn, A.
    Gottfried, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [2] Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations
    Yoon, Shinkyo
    Lee, Dae Ho
    Kim, Sang-We
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (01)
  • [3] Randomized Trial of Gefitinib with and without Pemetrexed as First-Line Therapy in East-Asian Patients with Advanced NS NSCLC with EGFR Mutations
    Cheng, Ying
    Murakami, Haruyasu
    Yang, Pan-Chyr
    He, Jianxing
    Nakagawa, Kazuhiko
    Kang, Jin Hyoung
    Kim, Joo-Hang
    Puri, Tarun
    Orlando, Mauro
    Wang, Xin
    Enatsu, Sotaro
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S206 - S206
  • [4] Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Cheng, Ying
    Murakami, Haruyasu
    Yang, Pan-Chyr
    He, Jianxing
    Nakagawa, Kazuhiko
    Kang, Jin Hyoung
    Kim, Joo-Hang
    Wang, Xin
    Enatsu, Sotaro
    Puri, Tarun
    Orlando, Mauro
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) : 3258 - +
  • [5] Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib
    Nie, Xin
    Zhang, Ping
    Cheng, Gang
    Wu, Xiao-Nan
    Li, Lin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (01) : 150 - 155
  • [6] Management of patients with epidermal growth factor receptor mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.
    Hosomi, Yukio
    Tanai, Chiharu
    Yoh, Kiyotaka
    Goto, Yasushi
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Lopes, G.
    Segel, J.
    Tan, D. S. W.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Kim, Young Hak
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 692 - +
  • [9] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    H Asahina
    K Yamazaki
    I Kinoshita
    N Sukoh
    M Harada
    H Yokouchi
    T Ishida
    S Ogura
    T Kojima
    Y Okamoto
    Y Fujita
    H Dosaka–Akita
    H Isobe
    M Nishimura
    British Journal of Cancer, 2006, 95 : 998 - 1004
  • [10] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Asahina, H.
    Yamazaki, K.
    Kinoshita, I.
    Sukoh, N.
    Harada, M.
    Yokouchi, H.
    Ishida, T.
    Ogura, S.
    Kojima, T.
    Okamoto, Y.
    Fujita, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004
12345